Current stage-Stage III-III-B Posts on Medivizor
Navigation Menu

Current stage-Stage III-III-B Posts on Medivizor

New targeted therapies have potential to improve overall survival for patients with EGFR-mutation positive NSCLC

Posted by on Aug 8, 2018 in Lung cancer | 0 comments

In a nutshell This study compared dacomitinib (PF-00299804) to gefitinib (Iressa) as a first treatment for patients with EGFR-mutation positive non-small-cell lung cancer. The authors concluded that treatment with dacomitinib provided an improved overall survival compared to gefitinib. Some background Current cancer therapy heavily...

Read More

Looking for patients with advanced squamous cell non-small-cell lung cancer or head and neck squamous cell carcinoma to test a new type of immunotherapy

Posted by on Dec 20, 2017 in Lung cancer | 0 comments

In a nutshell This phase 1 trial is examining the safety and effectiveness of a new type of immunotherapy. The treatment involves genetically enhancing patients’ own immune cells to better fight advanced non-small-cell lung cancer (NSCLC) or head and neck cancer. The main outcome to be measured will be the highest safe dose of the treatment. This...

Read More

Identifying factors to predict treatment prognosis in EGFR positive non-small-cell lung cancer

Posted by on Sep 10, 2017 in Lung cancer | 0 comments

In a nutshell The authors examined whether the lymphocyte to monocyte ratio (LMR) could predict outcome in patients with late stage EGFR positive non-small-cell lung cancer (NSCLC). They concluded LMR could be beneficial in predicting outcome for patients with EGFR positive NSCLC patients receiving first-line EGFR-TKIs.   Some background Some...

Read More

The safety and effectiveness of atezolizumab in PD-L1 advanced non-small cell lung cancer

Posted by on Aug 5, 2017 in Lung cancer | 0 comments

In a nutshell This trial looked at the effectiveness and safety of an immunotherapy drug, atezolizumab (Tecentriq). The authors concluded that this drug is effective and safe to treat patients with advanced non-small-cell lung cancer who have high levels of the PD-L1 protein. Some background Immunotherapy is a fairly new type of cancer treatment....

Read More

Combining chemotherapy and immunotherapy for advanced NSCLC

Posted by on Nov 14, 2016 in Lung cancer | 0 comments

In a nutshell This trial determined whether combining chemotherapy and immunotherapy would be beneficial for patients with advanced non-small-cell lung cancer (NSCLC). The authors concluded that a combination of chemotherapy agents, carboplatin (Paraplatin) and pemetrexed (Alimta), with the immunotherapy agent pembrolizumab (Keytruda) was tolerable and...

Read More

Is there a link between weight gain and treatment outcomes for non small cell lung cancer?

Posted by on Aug 22, 2016 in Lung cancer | 0 comments

In a nutshell This study examined the link between weight gain and survival in patients with non-small-cell lung cancer (NSCLC). The authors concluded that patients who experience weight gain during treatment have a survival  benefit compared to those who continue to lose weight.  Some background Unintentional weight loss occurs among...

Read More

Adding bevacizumab to letrozole treatment in hormone receptor-positive metastatic breast cancer – A good idea?

Posted by on Jul 18, 2016 in Breast cancer | 0 comments

In a nutshell This study looked at the effect of adding bevacizumab (Avastin) to letrozole (Femara) treatment in patients with hormone receptor-positive (HR+) metastatic (spread to other areas) breast cancer. They found that bevacizumab treatment prolonged the amount of time before patients experienced worsening of their...

Read More